瑞舒伐他汀与辛伐他汀治疗高脂血症临床疗效比较  

Comparative study of efficacy of rosuvastatin and simvastatin for hyperlipidemia

作　　者：蒋丽[1] 覃香[2] 赖呈谋[2] 

机构地区：[1]广西科技大学第一附属医院药剂科,广西柳州545001 [2]广西科技大学第一附属医院内科,广西柳州545001

出　　处：《海南医学》2017年第9期1406-1408,共3页Hainan Medical Journal

摘　　要：目的比较瑞舒伐他汀与辛伐他汀治疗高脂血症的疗效及安全性。方法选择2015年6月至2016年6月期间我院收治的128例高脂血症患者为研究对象,根据随机数表法随机分为观察组(n=64)与对照组(n=64),分别予瑞舒伐他汀(5 mg/d)与辛伐他汀(10 mg/d)治疗,疗程均为8周。比较两组患者治疗前后的血脂变化及不良反应发生情况。结果治疗后,观察组与对照组患者的甘油三脂(TG)、胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)分别为(1.88±0.21)mmol/L、(4.28±1.28)mmol/L、(2.48±0.97)mmol/L和(1.94±0.19)mmol/L、(4.44±1.35)mmol/L、(3.04±1.02)mmol/L,均较治疗前的(2.38±0.36)mmol/L、(6.25±2.34)mmol/L、(4.79±1.28)mmol/L和(2.25±0.23)mmol/L、(6.04±2.41)mmol/L、(4.86±1.36)mmol/L明显下降,高密度脂蛋白胆固醇(HDL-C)为(1.38±0.29)mmol/L和(1.34±0.41)mmol/L,均较治疗前的(1.25±0.34)mmol/L和(1.22±0.35)mmol/L明显上升,差异均有统计学意义(P<0.05);治疗后观察组患者仅LDL-C明显低于对照组(P<0.05),差异均无统计学意义(P>0.05);观察组患者的LDL-C达标率为82.81%,明显高于对照组的62.50%,差异均有统计学意义(P<0.05);两组患者均未发现药物相关严重不良反应。结论瑞舒伐他汀与辛伐他汀均可有效调节高脂血症患者血脂水平,但是瑞舒伐他汀降LDL-C的效果更加明显,且具有较好的用药安全性。Objective To compare the efficacy and safety of rosuvastatin and simvastatin for the treatment of hyperlipidemia. Methods According to the random number table method, 128 patients with hyperlipidemia in the First Affiliated Hospital of Guangxi University of Science and Technology from June 2015 to June 2016 as the research objects were divided into observation group（n=64） and control group（n=64）. The patients in the observation group were treated with rosuvastatin（5 mg/d）; meanwhile simvastatin（10 mg/d） was given to the patients in the control group. The treatment course in both groups was 8 weeks. The changes of serum lipids before and after treatment and adverse reactions in both groups were compared. Results After treatment, TG, TC and LDL-C in the observation group and control group were（1.88 ± 0.21） mmol/L,（4.28 ± 1.28） mmol/L,（2.48 ± 0.97） mmol/L and（1.94 ± 0.19） mmol/L,（4.44 ± 1.35） mmol/L,（3.04 ± 1.02） mmol/L, which were lower than（2.38 ± 0.36） mmol/L,（6.25 ± 2.34） mmol/L,（4.79 ± 1.28） mmol/L and（2.25±0.23） mmol/L,（6.04±2.41） mmol/L,（4.86±1.36） mmol/L before treatment. The HDL-C after treatment in the observation group and control group were（1.38±0.29） mmol/L and（1.34±0.41） mmol/L, which were higher than [（1.25±0.34） mmol/L and（1.22±0.35） mmol/L] before treatment（P〈0.05）. After treament, only LDL-C in the observation group was significantly lower than that in the control group（P〈0.05）, but no significant differences in the other indexes were found（P〉0.05）. The LDL-C compliance rate in observation group was 82.81%, which was significantly higher than62.50% of the control group, showing significant difference（P〈0.05）. There were no serious adverse drug reactions in both groups. Conclusion The combined application of rosuvastatin and simvastatin can both effectively regulate the blood lipid levels in patients with hyperlipidemia, but rosuvastatin has better effect in reducing the effect of

关 键 词：高脂血症 瑞舒伐他汀 辛伐他汀 动脉粥样硬化 

分 类 号：R589.2[医药卫生—内分泌]